Kalmár Alexandra, Galamb Orsolya, Szabó Gitta, Pipek Orsolya, Medgyes-Horváth Anna, Barták Barbara K, Nagy Zsófia B, Szigeti Krisztina A, Zsigrai Sára, Csabai István, Igaz Péter, Molnár Béla, Takács István
Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, 1083 Budapest, Hungary.
MTA-SE Molecular Medicine Research Group, Eötvös Loránd Research Network, 1083 Budapest, Hungary.
Cancers (Basel). 2023 Jan 31;15(3):907. doi: 10.3390/cancers15030907.
Analysis of circulating cell-free DNA (cfDNA) of colorectal adenoma (AD) and cancer (CRC) patients provides a minimally invasive approach that is able to explore genetic alterations. It is unknown whether there are specific genetic variants that could explain the high prevalence of CRC in Hungary. Whole-exome sequencing (WES) was performed on colon tissues (27 AD, 51 CRC) and matched cfDNAs (17 AD, 33 CRC); furthermore, targeted panel sequencing was performed on a subset of cfDNA samples. The most frequently mutated genes were , , and in AD, while , , , and were the most frequently mutated in CRC tissue. Variants in codons 12 (AD: 8/27, CRC: 11/51 (0.216)) and 13 (CRC: 3/51 (0.06)) were the most frequent in our sample set, with G12V (5/27) dominance in ADs and G12D (5/51 (0.098)) in CRCs. In terms of the cfDNA WES results, tumor somatic variants were found in 6/33 of CRC cases. Panel sequencing revealed somatic variants in 8 out of the 12 enrolled patients, identifying 12/20 tumor somatic variants falling on its targeted regions, while WES recovered only 20% in the respective regions in cfDNA of the same patients. In liquid biopsy analyses, WES is less efficient compared to the targeted panel sequencing with a higher coverage depth that can hold a relevant clinical potential to be applied in everyday practice in the future.
对结直肠腺瘤(AD)和癌症(CRC)患者的循环游离DNA(cfDNA)进行分析,提供了一种能够探索基因改变的微创方法。目前尚不清楚是否存在特定的基因变异可以解释匈牙利CRC的高发病率。对结肠组织(27例AD,51例CRC)和匹配的cfDNA(17例AD,33例CRC)进行了全外显子组测序(WES);此外,对一部分cfDNA样本进行了靶向测序。AD中最常发生突变的基因是 、 和 ,而CRC组织中最常发生突变的是 、 、 和 。密码子12(AD:8/27,CRC:11/51(0.216))和13(CRC:3/51(0.06))的变异在我们的样本集中最为常见,在AD中G12V(5/27)占主导,在CRC中G12D(5/51(0.098))占主导。就cfDNA WES结果而言,在6/33的CRC病例中发现了肿瘤体细胞变异。靶向测序显示,12名入组患者中有8名存在体细胞变异,在其靶向区域鉴定出12/20个肿瘤体细胞变异,而WES在同一患者的cfDNA相应区域仅检测到20%。在液体活检分析中,与具有更高覆盖深度的靶向测序相比,WES效率较低,靶向测序在未来日常实践中具有相关临床应用潜力。